Dr Yoshiya (Josh) Yamada, MDCo-Chair ITRO 2020
Prof Michael Zelefsky, MDChief of Memorial Sloan Kettering’s Brachytherapy Service
Dr Kaled Alektiar, MDRadiation Oncologist
Dr Igor Barani, MDAssociate Professor and Interim Chair in Radiation Oncology
Prof Chris Beltran, PhDChair of Physics and Director: Technical Operations of Particle Therapy
Dr Jimmy Caudell, PhDRadiation Oncologist
Prof Laura Dawson, MDRadiation Oncologist
Prof Joseph Deasy, PhDChair of the Department of Medical Physics
Prof Vladimir Feygelman, PhDMedical Physicist
Prof Cynthia Menard, MDRadiation Oncologist
Prof Roberto Orecchia, MDScientific Director of IEO
Prof Carl Rossi, MDMedical Director/Physician
Prof Wolfgang Tomé, PhDChief, Division of Therapeutic Medical Physics
Memorial Sloan Kettering Cancer Center
Dr Yoshiya (Josh) Yamada, MD
Dr. Yamada is an Associate Attending Radiation Oncologist and member of the brachytherapy service in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is a graduate of the Faculty of Medicine at the University of Alberta and completed residency training in Radiation Oncology at the Princess Margaret Hospital at the University of Toronto. He completed a fellowship in brachytherapy at Memorial Sloan Kettering Cancer Center and has been a faculty member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center for over 15 years. He has an academic interest in prostate cancer, brachytherapy, and spine radiosurgery, and has published widely on these topics. He has been invited to lecture on these topics both nationally and internationally. He and his wife Susy are the proud parents of five children. He as a special place in his heart for Australia!
Memorial Sloan Kettering Cancer Center, USA
Prof Michael Zelefsky, MD
I am a board-certified radiation oncologist and co-leader of Memorial Sloan Kettering’s Genitourinary Disease Management Team — a multidisciplinary group of physicians who work together to treat patients with urologic malignancies. As a recognized expert in the field of radiation therapy, I am Chief of Memorial Sloan Kettering’s Brachytherapy Service. Brachytherapy, which we use to treat many types of cancer, is the delivery of radiation using seeds implanted directly in a tumor.
Our prostate brachytherapy program, which I have helped develop and enhance since joining the staff in 1990, is known for its depth of experience and cutting-edge approach in treating men with prostate cancer. For patients with advanced or aggressive prostate cancer, I have significant expertise using high-dose-rate brachytherapy and temporary brachytherapy, in which patients receive several high-dose treatments either as a boost or as the sole treatment. I also have experience using brachytherapy in patients whose tumor has recurred after external-beam radiation therapy or seed implant, as well as expertise using image-guided stereotactic radiosurgery for areas of metastases (spread) such as bone or lymph nodes.
In addition, I was instrumental in pioneering the use of IMRT (intensity-modulated radiation therapy, which is computer-guided delivery of high doses of radiation directly to the tumor) and IGRT (image-guided radiotherapy, radiation beams targeted precisely to the tumor) for treating men with prostate cancer.
I am Editor-in-Chief of Brachytherapy, a medical journal that addresses all aspects of this sub-specialty, and Chairman of the National Patterns of Care Study for Genitourinary Cancers. I am a past president of the American Brachytherapy Society.
For my work in this field, I have been honored to receive several awards including the Boyer Award for Excellence in Clinical research, the Outstanding Teaching Award in the Department of Radiation Oncology at Memorial Sloan Kettering, the 2009 Henschke Medal (the highest award of the American Brachytherapy Society for achievements in Brachytherapy), and the 2009 Emanuel Van Descheuren Award for Excellence in Translational Research.
I lecture nationally and internationally about radiation treatments for prostate cancer.
Memorial Sloan Kettering Cancer Center, USA
Dr Kaled Alektiar, MD
Information to come
Barrow Neurological Institute
Dr Igor Barani, MD
Mayo Clinic Jacksonville Florida USA
Prof Chris Beltran, PhD
Accelerator Physics. His thesis research was conducted at the Los Alamos National Laboratory in Los Alamos, New Mexico, USA. After completion of graduate school, Dr. Beltran accepted a medical physics fellowship at Mayo Clinic in Rochester, Minnesota. Upon completion of the 3 year fellowship he accepted an Assistant Professor position at St. Jude Children’s Research Hospital in Memphis, Tennessee. After 5 years in that position Dr. Beltran moved back to Mayo Clinic to aid in the Proton Therapy Center at Mayo Clinic.
Mayo Clinic is bringing online 2 spot scanning proton treatment facilities, one in Rochester Minnesota and the other in Phoenix Arizona. Each facility has 5 treatment rooms; 4 gantry rooms and one fixed beam room. This presentation will describe the proton facility and anticipated patient workflow. We will also introduce our research endeavours to address 4 critical shortcomings in spot scanning proton treatments. The first is the limitation in accuracy of traditional analytical dose calculations; second is the need for robust optimization; third is the uncertainty in proton stopping power determination; and lastly is the variation of the relative biological effectiveness of proton treatments with LET.
Moffitt Cancer Center, USA
Dr Jimmy Caudell, PhD
Dr. Caudell’s clinical interests include treatment of head and neck cancer and cutaneous malignancies with radiotherapy. Research interests include prediction of radiation sensitivity, evaluation of novel radiosensitizers and radioprotectants, as well as the use of technology to improve radiation delivery for head and neck cancer. Dr. Caudell is currently co-PI on the national NRG HN-002 prospective clinical trial testing methods to reduce toxicity for patients with low risk oropharyngeal HPV positive H&N cancer. In addition, Dr. Caudell is PI on a phase I dose escalation trial of H&N SBRT with concurrent chemotherapy for patients with recurrent, unresectable H&N cancer.
He is also PI of a grant to predict the benefit of post-operative radiotherapy in H&N cancer using a gene expression signature of tumor radiosensitivity. Dr. Caudell continues his research through retrospective analysis of patients treated for H&N malignancies (primary and metastatic). Dr. Caudell’s research has focused primarily on treatment outcomes with respect to both cancer control and toxicity.
From a clinical standpoint, his work on treatment planning and dysphagia following radiation treatment has been nationally recognized. He also has performed research in treatment disparities and novel radiation delivery techniques for head and neck cancer. Dr. Caudell’s role in many collaborative projects is to provide clinical expertise regarding the outcomes and toxicities associated with radiation treatment for H&N cancers.
While at Moffitt Dr. Caudell has been instrumental in the development of the H&N/Endocrine Clinical Pathways, serves on the MMG Revenue Cycle Committee and Center of Excellence in Cancer Imaging and Technology, and has been a member of Moffitt’s Scientific Symposium Committee. As an educator, Dr. Caudell works closely with the Radiation Oncology Residency Clinical Competency Committee and provides consistent mentorship to our Radiation Oncology Residents through clinic rotations and lectures. Lecture topics for the Department of Otolaryngology of the University of South Florida and Moffitt H&N Symposium include “Chemoradiation of the Head and Neck” and “Current Management of Locally Advanced HPV-Negative Head & Neck Cancer.” Dr. Caudell currently serves as H&N Service Chief and has added the H&N SBRT Program.
Outside of Moffitt Dr. Caudell is a member of the RTOG/NRG H&N Steering Committee, RTOG 1016 QA Committee, National Comprehensive Cancer Network (NCCN) H&N Panel and H&N Radiation Oncology Sub-Committee.
Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada
Prof Laura Dawson, MD
Dr Laura Dawson is a radiation oncologist at the Princess Margaret Cancer Centre, and a Professor the Department of Radiation Oncology, University of Toronto. She completed her medical school and radiation oncology residency at the University of Toronto and a fellowship in high precision radiation therapy at the University of Michigan, where she stayed on as a faculty member until 2003, at which time she returned to Canada to develop a hepatobiliary radiation
therapy program at the Princess Margaret Cancer Centre.
She is an internationally recognized leader in hepatobiliary and liver metastases radiation therapy and in the use of advanced radiation technologies, including stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT). She is the principal investigator of several phase III clinical trials, including RTOG1112, an international randomized trial of SBRT for locally advanced hepatocellular carcinoma and HE.1, a Canadian randomized trial of low dose whole liver radiation therapy to treat painful liver cancer, unsuitable for other treatment.
She has published over 150 scientific papers. She was a recipient of an ASCO career development award, and her research has been funded by the NIH, CIHR, NCIC CTG, and the Canadian Cancer Society.
Memorial Sloan Kettering Cancer Center, in New York City
Prof Joseph Deasy, PhD
Chair of the Department of Medical Physics and Chief of the Service for Predictive Informatics
I am an attending physicist with expertise in applying statistical modeling to the analysis of large, complex datasets in order to understand the relationship between treatment, patient, and disease characteristics and the probability of local control and normal tissue toxicity. My group’s research has focused specifically on algorithms that can be used to optimize treatment planning dose-distribution characteristics (calculating the best way to deliver increased radiation to the tumor while reducing radiation to surrounding tissue) and modeling the probability of treatment success (tumor eradication) and normal tissue complications as the radiation dose distribution varies.
Department of Radiation Oncology, Moffitt Cancer Center, USA
Prof Vladimir Feygelman, PhD
Vladimir M. Feygelman graduated from the Department of Physics at Rostov State University in the former U.S.S.R in 1982 with a degree in Laser Physics. In 1985 he was awarded a PhD in Physical Chemistry at the same university. Since 1990 Dr. Feygelman is involved in Medical Physics, first as a Post Doc at the University of Florida (Gainesville), and then as a clinical radiotherapy physicist in Canada and USA. In 2006 he joined the faculty of Moffitt Cancer Center. Currently he is a Senior Faculty Member at Moffitt and Professor at USF Department of Oncologic Sciences. Dr. Feygelman divides his time between clinical duties, research, and teaching physics PhD students and medical residents. As a senior physicist, he is responsible for the implementation of all major technological developments at the Department of Radiation Oncology. His research interests are primarily focused on quality assurance of complex advanced treatments. Dr. Feygelman was a member of the AAPM Task Group 244 on commissioning of dose calculations. He was the principal writer of the IMRT/VMAT section. Currently he serves as a Co-Chair of the AAPM working group on reference dose specification in treatment planning systems. Dr. Feygelman is an author of over 50 peer-reviewed papers on Medical Physics and was an invited speaker at various national and international meetings such as AAPM, ESTRO, and IEEE.
Department of Radiation Oncology, CHUM
Prof Cynthia Menard, MD
The primary focus of my scholarly activity is to better individualize radiation therapy through the development, validation, and clinical application of magnetic resonance imaging techniques to radiation treatment planning, response assessment, and treatment adaptation.
I have specifically invested my efforts to improving radiotherapy to the brain and for prostate cancer.
Director of Radiation Therapy Department, IEO Milan Italy
Prof Roberto Orecchia, MD
He was graduated from the University of Turin and in the post doc period obtained degrees in Radiotherapy, Medical Oncology and Diagnostic Imaging. Since 1994, he is Full Professor in Radiotherapy at the University of Milan and Director of the Radiology Science Department at IEO (European Institute of Oncology). Since January 2015 he is Scientific Director at the (IEO), in Milan, and at the CNAO Foundation, the first centre for hadrontherapy built in Italy, providing proton and carbon ion beams. His clinical and research activities focuse on different fields of radiation therapy and oncology, being since the beginning characterized by a strong interest for innovation. He published totally up to date more than three hundred fifty scientific papers on journals listed in the Pub-Med.
Prof Carl Rossi, MD
Dr. Rossi has personally treated more than 10,000 prostate cancer patients with proton radiation over the last 26 years—more than any other physician in the world.
Internationally recognized for his achievements in cancer treatment, Dr. Rossi is a radiation oncologist with a research focus on the quality of life and cure rate in prostate cancer and lymphoma. Specializing in proton beam therapy, he has been treating prostate cancer patients with proton therapy since 1991. Prior to serving as the Medical Director of California Protons, he was the Medical Director of the Scripps Proton Therapy Center and was an Associate Professor in the Department of Radiation Medicine at the Loma Linda University Medical Center. He is currently a Clinical Professor of Radiation Medicine at UC San Diego.
Montefiore Medical Center, Albert Einstein College of Medicine
Prof Wolfgang Tomé, PhD
A) Mitigation of normal tissue radiation injury in the brain. One example of this research thrust is Hippocampal Avoidance Whole Brain Radiotherapy (HAWBRT): While whole brain radiotherapy (WBRT) combined with Stereotactic radiosurgery offers effective palliation in many inoperable cases, it has been speculated that adverse effects on neurocognitive function might outweigh its benefits. HAWBRT aims to preserve neurocognitive function and quality of life, and the Risk to Benefit ratio will have to be optimized with respect to these endpoints. In our work involving patients receiving focal fractionated stereotactic radiotherapy for benign and low grade brain neoplasms, we have established a hippocampal dosimetric threshold of 7.3 Gy in 2 Gy fraction equivalents to 40% of the hippocampus that is associated with subsequent risk of impairment in delayed recall. Patients receiving a dose of higher than this threshold dose to 40% of the hippocampus are 19 times more likely to exhibit impairment in list learning than patients that receive less than this threshold dose to 40% of the hippocampus. As demonstrated by us this dosimetric threshold can be achieved with currently available IMRT techniques and it may therefore, be desirable to spare a patient’s hippocampus during WBRT to achieve a durable palliative effect with decreased neurocognitive side effects in the memory domain. Using animal models we are interested in further investigating the link between hippocampal irradiation and neurocognitive impairment.
B) MR-Guided Therapy
C) Development of decision support systems for adaptive radiation therapy.
D) Use of functional imaging to define and characterize high-risk volumes for risk adaptive radiotherapy. Risk adaptive radiotherapy is a biological optimization strategy that is based on the possible risk characteristics for local recurrence in tumor sub-volumes rather than individual tumor voxels and treatment plans are optimized using biological objective functions that are region specific, rather than voxel specific. Risk Adaptive optimization can be employed in the generation of treatment plans based on biological objective functions.
E) Use of functional imaging to assess treatment response of tumors to therapy.
F) Use of nonlinear systems theory to predict and eventually control (i.e. stabilize) the breathing pattern and hence the tumor motion based on fast intratreatment fraction MR imaging using real time MR radiotherapy systems. Develop real-time adaptive RT techniques that can correct for changes on the fly.
G) Further development of advanced dosimetry systems for spot scanning proton dosimetry and further development of proton CT stopping power images for daily Bragg Peak prediction prior to the delivery of IMPT.